Aortic Aneurysm Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

An aortic aneurysm is a permanent, localised dilation of the aorta to at least 1.5 times its normal diameter — corresponding to greater than 3.0 cm in the abdominal aorta and greater than 3.5 cm in the thoracic aorta. The natural history of aneurysms is one of progressive enlargement, as the law of Laplace dictates that wall tension increases with expanding radius, accelerating growth and eventual rupture. Rupture of an aortic aneurysm carries 80–90% overall mortality (including pre-hospital deaths), making elective repair at appropriate size thresholds a life-saving intervention.

Abdominal aortic aneurysms (AAA) — most commonly involving the infrarenal aorta — affect approximately 3–7% of men above 65 years in Western populations; risk factors include male sex, smoking (the most powerful modifiable risk factor), hypertension, hyperlipidaemia, family history, and atherosclerosis. Thoracic aortic aneurysms (TAA) — involving the ascending aorta, aortic arch, or descending thoracic aorta — have different pathophysiology: ascending aortic aneurysms are most commonly due to medial degeneration (cystic medial necrosis), with genetic connective tissue disorders (Marfan syndrome, Loeys-Dietz syndrome, bicuspid aortic valve-associated aneurysmopathy) accounting for a significant proportion, particularly in younger patients.

Two fundamentally different repair approaches exist: open surgical repair (OSR), which involves direct surgical access, cross-clamping of the aorta, and replacement with a synthetic prosthetic graft (Dacron or PTFE) under general anaesthesia; and endovascular repair — endovascular aortic repair (EVAR) for infrarenal AAA, or thoracic EVAR (TEVAR) for descending thoracic aortic aneurysms — where a stent graft is delivered percutaneously via the femoral arteries and deployed within the aneurysm sac to exclude it from the circulation.

Infrarenal abdominal aortic aneurysms (AAA) are the most common indication, with elective repair recommended when diameter exceeds 5.5 cm in men and 5.0 cm in women (US and UK guidelines — this threshold is reached due to the higher rupture risk per unit size in women), or when growth exceeds 1 cm/year at any diameter. Symptomatic AAAs (causing back, flank, or abdominal pain) require urgent repair regardless of size. Ruptured AAAs constitute a surgical emergency with immediate operative intervention.

Thoracic aortic aneurysms have higher rupture thresholds per unit size than abdominal aneurysms. Ascending aortic aneurysms are repaired when diameter exceeds 5.5 cm (or 5.0 cm in patients with bicuspid aortic valve or Marfan syndrome due to higher risk). Aortic root aneurysms may require valve-sparing root replacement (David or Yacoub procedure) to preserve the native aortic valve, or composite graft replacement (Bentall procedure — simultaneous aortic valve replacement and root replacement with reimplantation of coronary arteries). Descending thoracic aneurysms above 6.0 cm are typically treated by TEVAR. Aortic dissection (Type A — involving the ascending aorta) requires emergency surgical repair; Type B dissections (confined to the descending thoracic aorta) are initially managed medically with tight blood pressure control, with TEVAR reserved for complicated dissections.

Anatomical eligibility for EVAR versus open surgical repair depends on aortic morphology. EVAR requires: adequate infrarenal aortic neck length (greater than 10–15 mm) and neck angulation below 60 degrees for proximal sealing; adequate iliac artery access calibre (generally above 7–8 mm in diameter); absence of severe neck thrombus or calcification compromising seal; and neck diameter within the device's specified range. Approximately 60–70% of AAA patients are anatomically suitable for EVAR. Patients not suitable for EVAR due to hostile anatomy require open repair if they are fit for surgery.

Cardiac, pulmonary, and renal function are assessed pre-operatively: EVAR is generally preferred in elderly, high-cardiac-risk patients due to lower perioperative mortality compared to OSR (EVAR-1 and DREAM trials confirm lower 30-day mortality with EVAR). Open repair is preferred in younger, low-risk patients (below 65–70 years) because long-term freedom from reintervention and long-term survival are superior with open repair, avoiding the need for lifelong imaging surveillance required after EVAR to monitor for endoleaks and stent graft migration. Patients with connective tissue disorders (Marfan, Loeys-Dietz) should undergo open repair rather than EVAR due to ongoing aortic wall fragility.

Open surgical repair of infrarenal AAA is performed via a midline or flank (retroperitoneal) approach, with aortic cross-clamping above and below the aneurysm, opening of the sac, placement of a tube or bifurcated Dacron graft, and aneurysm sac closure over the graft. The operation requires 3–5 hours under general anaesthesia, with intensive care unit stay of 1–2 days and total hospital stay of 7–10 days. Long-term results are excellent — a well-performed open repair lasts a lifetime without further intervention in the majority of patients, with 30-year post-repair data showing normal life expectancy once the early perioperative period is survived.

EVAR for infrarenal AAA uses a commercially manufactured modular stent graft system (Medtronic Endurant, Cook Zenith, Gore Excluder, Endologix AFX among others) deployed via bilateral femoral arteriotomies under fluoroscopic guidance, typically under general or regional (epidural/spinal) anaesthesia. Hospital stay is 2–4 days, recovery time 1–2 weeks. EVAR requires lifelong annual CT surveillance to detect endoleaks (continued blood flow into the aneurysm sac from incomplete stent graft seal — occurring in 15–30% of cases over 10 years), stent migration, limb occlusion, and aneurysm sac enlargement. Approximately 15–25% of EVAR patients require reintervention within 10 years for endoleak or device failure — a substantially higher reintervention rate than open repair.

For complex (juxta/pararenal/suprarenal) AAAs extending above the renal arteries, fenestrated EVAR (FEVAR) or branched EVAR (BEVAR) with customised stent grafts incorporating reinforced fenestrations or side branches to maintain renal, superior mesenteric, and coeliac artery perfusion, allow endovascular treatment at the cost of significantly higher procedural complexity and 3–4 month wait for device fabrication.

For unruptured AAA, elective repair prevents rupture — the 5-year rupture risk of a 6 cm AAA is approximately 25–40%, dramatically reduced to near-zero by successful elective repair. The EVAR-1 trial established that EVAR offers a 30-day mortality advantage over open repair (1.8% vs 4.3%) for infrarenal AAA, though at 8 years, total mortality is equivalent between the two approaches due to EVAR-related late complications. Open repair, when successfully performed, restores a normal aortic architecture with highly durable long-term results.

For ascending aortic aneurysms, elective repair at the appropriate threshold (5.5 cm) prevents aortic dissection and rupture — both highly lethal events — with elective surgical mortality of 1–3% at high-volume centres. For patients with bicuspid aortic valve and associated aortic root/ascending aortic aneurysm, simultaneous valve repair or replacement at the time of aneurysm surgery corrects both pathologies in a single operation. Valve-sparing root replacement (VSARR — David procedure) preserves the native aortic valve in suitable patients with aortic root aneurysm and anatomically normal leaflets, avoiding lifetime anticoagulation while achieving excellent long-term root stability.

Open AAA repair carries 30-day mortality of 1.5–3% at high-volume centres for elective cases, rising to 5–8% in octogenarians and to 40–50% for ruptured AAA. Renal failure (requiring temporary or permanent dialysis) occurs in 3–5% due to renal ischaemia during aortic cross-clamping above the renal vessels or embolisation of atheromatous debris. Spinal cord ischaemia causing paraplegia is rare in infrarenal AAA repair (below 1%) but a major concern in thoracoabdominal aneurysm repair (3–8% risk), mitigated by cerebrospinal fluid drainage, staged repair, and maintenance of spinal cord perfusion pressure. Wound complications (hernia, lymph fistula) occur in 5–10%. Sexual dysfunction from division of the inferior mesenteric artery and pelvic autonomic nerves occurs in 15–20% of men.

EVAR carries lower perioperative mortality but the late complication profile is substantial. Endoleak — defined as persistent blood flow within the excluded aneurysm sac — occurs in 15–30% over 10 years; most significant are Type I endoleaks (incomplete proximal or distal seal) and Type III endoleaks (device component disconnection), which mandate reintervention. Stent graft limb thrombosis (5% at 5 years), limb kinking, and stent migration are further late complications requiring re-intervention. The EVAR-1 trial's 15-year follow-up showed that open repair significantly outperformed EVAR in long-term survival among initially fit patients — an important finding driving greater selectivity in EVAR use for younger, anatomically fit patients.

After open AAA repair, patients typically spend 1–2 days in ICU and 5–7 more days on the surgical ward, with total hospital stay of 7–10 days. Return to normal activity including driving takes 6–8 weeks; heavy lifting is restricted for 3 months to allow abdominal wall healing. Long-term, open repair patients require abdominal ultrasound or CT at 5 years (or sooner if symptomatic) to monitor for anastomotic pseudoaneurysm, graft limb stenosis, or new aneurysm formation. Annual review with blood pressure monitoring and optimal medical management (antiplatelet therapy, statin, BP control) is recommended indefinitely.

After EVAR, clinical and radiological surveillance is mandatory for life — detecting late endoleak and aneurysm sac expansion (which indicates inadequate exclusion and persistent rupture risk) is essential because EVAR-related deaths from late rupture do occur. Standard surveillance protocol is CT angiography at 1, 6, 12 months, then annually. Some centres use duplex ultrasound to reduce radiation exposure in low-risk, non-complex EVAR cases on intermediate surveillance visits.

In the United States, elective EVAR for infrarenal AAA costs $25,000–$60,000; open AAA repair costs $30,000–$80,000 with the higher cost reflecting longer ICU stay. Thoracic aortic aneurysm repair (ascending with cardiopulmonary bypass) costs $60,000–$150,000. Fenestrated or branched EVAR (FEVAR/BEVAR) at specialised centres costs $80,000–$150,000. These figures represent a substantial barrier for patients without comprehensive surgical insurance coverage.

For international patients, vascular and cardiac surgical expertise for aortic aneurysm repair is available at JCI-accredited centres in India, Thailand, and Singapore at dramatically lower cost. EVAR for infrarenal AAA in India costs $8,000–$18,000 at centres such as Apollo, Fortis, and Narayana Health. Open AAA repair costs $10,000–$20,000. Ascending aortic aneurysm repair with cardiopulmonary bypass costs $12,000–$25,000. These centres perform high volumes of complex cardiovascular surgery and maintain outcomes data. Thailand (Bangkok) and Singapore offer EVAR at $15,000–$35,000. Medical tourists should plan carefully for post-procedure surveillance imaging requirements and ideally have a cardiologist or vascular surgeon at home briefed on the procedure for follow-up coordination.

For AAA below the repair threshold, optimal medical management aims to slow aneurysm growth and reduce cardiovascular risk. Smoking cessation is the single most important intervention — smokers have 7–8 times higher AAA rupture risk and substantially faster growth rates than non-smokers. Anti-hypertensive therapy (particularly beta-blockers in Marfan syndrome) reduces haemodynamic stress on the aortic wall. Statins reduce aneurysm expansion rate modestly in observational studies. Surveillance ultrasonography at 6–12 monthly intervals for aneurysms 4–5.4 cm monitors growth and determines the appropriate timing for elective repair.

For ascending aortic aneurysm in Marfan syndrome, losartan — an ARB with TGF-beta inhibition properties — is used alongside beta-blockade to reduce aortic root growth rate, based on the COMPARE trial. Genetic counselling and family screening are indicated for heritable aortopathies (Marfan, Loeys-Dietz, TGFBR1/2 mutations, FBN1 mutations). For inoperable patients with severe comorbidities precluding both open and endovascular repair, the best available palliation is maximised medical management with careful symptom monitoring and frank goals-of-care discussion regarding the natural history.